Bristol Myers Squibb (BMY) – Research Analysts’ Weekly Ratings Changes

Bristol Myers Squibb (NYSE: BMY) has recently received a number of price target changes and ratings updates:

• 8/5/2026 – Bristol Myers Squibb is now covered by Raymond James Financial, Inc.. They set a “strong-buy” rating on the stock.
• 8/5/2026 – Bristol Myers Squibb is now covered by TD Cowen. They set a “buy” rating on the stock.
• 8/5/2026 – Bristol Myers Squibb was downgraded by UBS Group AG from “buy” to “neutral”.
• 8/5/2026 – Bristol Myers Squibb was downgraded by Jefferies Financial Group Inc. from “buy” to “hold”.
• 8/5/2026 – Bristol Myers Squibb is now covered by Roth Capital. They set a “buy” rating and a $75.00 price target on the stock.
• 8/5/2026 – Bristol Myers Squibb was upgraded by Sanford C. Bernstein from “market perform” to “outperform”.
• 8/5/2026 – Bristol Myers Squibb is now covered by Piper Sandler. They set an “overweight” rating on the stock.
• 8/5/2026 – Bristol Myers Squibb was upgraded by Argus from “hold” to “buy”. They now have a $75.00 price target on the stock.
• 8/3/2026 – Bristol Myers Squibb had its “neutral” rating reaffirmed by Citigroup Inc.. They now have a $70.00 price target on the stock, up from $66.00.
• 7/31/2026 – Bristol Myers Squibb had its “neutral” rating reaffirmed by Cantor Fitzgerald. They now have a $59.00 price target on the stock, up from $54.00.
• 7/31/2026 – Bristol Myers Squibb had its “buy” rating reaffirmed by Guggenheim. They now have a $75.00 price target on the stock, up from $72.00.
• 7/31/2026 – Bristol Myers Squibb was given a new $65.00 price target by Wells Fargo & Company. They now have an “equal weight” rating on the stock.
• 7/31/2026 – Bristol Myers Squibb had its price target raised by Royal Bank Of Canada from $60.00 to $64.00. They now have a “sector perform” rating on the stock.
• 7/31/2026 – Bristol Myers Squibb had its price target raised by JPMorgan Chase & Co. from $67.00 to $73.00. They now have an “overweight” rating on the stock.
• 7/31/2026 – Bristol Myers Squibb had its “buy” rating reaffirmed by Truist Financial Corporation. They now have a $70.00 price target on the stock, up from $65.00.
• 7/30/2026 – Bristol Myers Squibb was upgraded by Weiss Ratings from “hold (c)” to “hold (c+)”.
• 7/27/2026 – Bristol Myers Squibb had its “market perform” rating reaffirmed by Raymond James Financial, Inc..
• 7/27/2026 – Bristol Myers Squibb had its “market perform” rating reaffirmed by BMO Capital Markets.
• 7/16/2026 – Bristol Myers Squibb was downgraded by Weiss Ratings from “hold (c+)” to “hold (c)”.
• 7/10/2026 – Bristol Myers Squibb had its price target lowered by Bank of America Corporation from $67.00 to $66.00. They now have a “buy” rating on the stock.
• 7/6/2026 – Bristol Myers Squibb had its “neutral” rating reaffirmed by Cantor Fitzgerald. They now have a $54.00 price target on the stock.
• 7/2/2026 – Bristol Myers Squibb had its “hold (c+)” rating reaffirmed by Weiss Ratings.
• 6/27/2026 – Bristol Myers Squibb was upgraded by Wall Street Zen from “buy” to “strong-buy”.

Bristol Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 3.9%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 55.51%.

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.